The reduced E-cadherin in primary SRCC supports its role during epithelial-mesenchymal transition (EMT) in tumor development and metastasis; however, its re-expression benefits tumor cells to form solid metastatic deposits [31]. The gene discussed is CDH1; the disease is neoplasm.